MedTech VC 2026: The Real Story vs. The Thesis

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 06 Oct, 13:00 UTC

I kept hearing “medtech VC is in decline,” so I decided to dig into the data myself. I expected shrinking investor interest, inflated valuations, and a weak exit environment. Instead, I found a more nuanced story. The post MedTech VC 2026: The Real Story vs. The Thesis appeared first on MedCity…